Pretreatment with G-CSF Could Enhance the Antifibrotic Effect of BM-MSCs on Pulmonary Fibrosis

Pretreatment with G-CSF Could Enhance the Antifibrotic Effect of BM-MSCs on Pulmonary Fibrosis

Granulocyte colony-stimulating factor (G-CSF) can promote the repair of a variety of damaged tissues, but the underlying mechanisms have not yet been fully elucidated. Bone marrow mesenchymal stem cells (BM-MSCs) play an important role in the repair of damaged tissue. The aim of this study was to ex...

Full description

Bibliographic Details
Main Authors:	Feiyan Zhao, Wei Liu, Shaojie Yue, Lei Yang, Qingzhong Hua, Yan Zhou, Haipeng Cheng, Ziqiang Luo, Siyuan Tang
Format:	Article
Language:	English
Published:	Hindawi Limited 2019-01-01
Series:	Stem Cells International
Online Access:	http://dx.doi.org/10.1155/2019/1726743

Similar Items

Antifibrotic and Regenerative Effects of Treamid in Pulmonary Fibrosis
by: Evgenii Skurikhin, et al.
Published: (2020-11-01)

Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat
by: Toby M. Maher, et al.
Published: (2019-09-01)

HDAC inhibitors as antifibrotic drugs in cardiac and pulmonary fibrosis
by: Xing Lyu, et al.
Published: (2019-07-01)

Efficacy of early antifibrotic treatment for idiopathic pulmonary fibrosis
by: Keishi Sugino, et al.
Published: (2021-07-01)

Antifibrotic therapy of idiopathic pulmonary fibrosis: efficiency / safety ratio
by: S. N. Avdeev, et al.
Published: (2018-10-01)

Antifibrotic Mechanism of Cinobufagin in Bleomycin-Induced Pulmonary Fibrosis in Mice
by: Xiaohe Li, et al.
Published: (2019-09-01)

Effect of sildenafil added to antifibrotic treatment in idiopathic pulmonary fibrosis
by: Jieun Kang, et al.
Published: (2021-09-01)

Outcomes for hospitalized patients with idiopathic pulmonary fibrosis treated with antifibrotic medications
by: Bryan T. Kelly, et al.
Published: (2021-07-01)

Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis
by: Bridget F. Collins, et al.
Published: (2019-10-01)

Antifibrotic drugs for idiopathic pulmonary fibrosis: What we should know?
by: Vijay Hadda, et al.
Published: (2020-01-01)

3D Spheroid Culture Enhances the Expression of Antifibrotic Factors in Human Adipose-Derived MSCs and Improves Their Therapeutic Effects on Hepatic Fibrosis
by: Xuan Zhang, et al.
Published: (2016-01-01)

Efficacy and tolerability of antifibrotic agents in idiopathic pulmonary fibrosis: An experience from Turkey
by: Onur Turan, et al.
Published: (2021-01-01)

The Human Umbilical Cord Tissue-Derived MSC Population UCX Promotes Early Motogenic Effects on Keratinocytes and Fibroblasts and G-CSF-Mediated Mobilization of BM-MSCs when Transplanted In Vivo
by: Joana P. Miranda, et al.
Published: (2015-05-01)

Fatigue in idiopathic pulmonary fibrosis measured by the Fatigue Assessment Scale during antifibrotic treatment
by: Line Kølner-Augustson, et al.
Published: (2021-01-01)

Evaluation of the Antifibrotic Effect of Serotonin Receptor Antagonists on Bleomycin Induced Pulmonary Fibrosis in Rats
by: Shimaa Z. Abd-Alla, et al.
Published: (2017-06-01)

Idiopathic pulmonary fibrosis in the era of antifibrotic therapy: Searching for new opportunities grounded in evidence
by: C. Robalo-Cordeiro, et al.
Published: (2017-09-01)

Antifibrotic therapies reduce mortality and hospitalization among Medicare beneficiaries with idiopathic pulmonary fibrosis
by: Broder, M.S, et al.
Published: (2021)

AT-MSCs Antifibrotic Activity is Improved by Eugenol through Modulation of TGF-β/Smad Signaling Pathway in Rats
by: Moustafa Fathy, et al.
Published: (2020-01-01)

Exosomes Derived from BM-MSCs Mitigate the Development of Chronic Kidney Damage Post-Menopause via Interfering with Fibrosis and Apoptosis
by: Abdelfattah-Hassan, A., et al.
Published: (2022)

Real-world retrospective observational study exploring the effectiveness and safety of antifibrotics in idiopathic pulmonary fibrosis
by: Peter Nightingale, et al.
Published: (2021-08-01)

Switching antifibrotics in patients with idiopathic pulmonary fibrosis: a multi-center retrospective cohort study
by: Yuzo Suzuki, et al.
Published: (2021-07-01)

Impact of novel antifibrotic therapy on patient outcomes in idiopathic pulmonary fibrosis: patient selection and perspectives
by: Graney BA, et al.
Published: (2018-09-01)

Antifibrotic treatment response and prognostic predictors in patients with idiopathic pulmonary fibrosis and exposed to occupational dust
by: Valeria Casillo, et al.
Published: (2019-09-01)

High-Resolution CT Change over Time in Patients with Idiopathic Pulmonary Fibrosis on Antifibrotic Treatment
by: Elisabetta Balestro, et al.
Published: (2019-09-01)

Reversal of hepatic fibrosis: pathophysiological basis of antifibrotic therapies
by: Ismail MH, et al.
Published: (2011-07-01)

BM-MSCs differentiated to chondrocytes for treatment of full-thickness cartilage defect of the knee
by: Rodrigo Mardones, et al.
Published: (2020-10-01)

The role of Smad7 in regulating bone remodeling, osteoporosis and BM-MSCs differentiation.
Published: (2014)

Prognostic significance of forced vital capacity decline prior to and following antifibrotic therapy in idiopathic pulmonary fibrosis
by: Yuya Aono, et al.
Published: (2020-09-01)

Comparing the renoprotective effects of BM-MSCs versus BM-MSC-exosomes, when combined with an anti-fibrotic drug, in hypertensive mice
by: Yifang Li, et al.
Published: (2021-12-01)

Antifibrotic Effect of Marine Ovothiol in an In Vivo Model of Liver Fibrosis
by: Mariarita Brancaccio, et al.
Published: (2018-01-01)

Antifibrotic effects of crocin on thioacetamide-induced liver fibrosis in mice
by: Mardi M. Algandaby
Published: (2018-05-01)

The Effects of Platelet-Rich and Platelet-Poor Plasma on Biological Characteristics of BM-MSCs In Vitro
by: Jiahui Zhang, et al.
Published: (2020-01-01)

BM-MSC-derived exosomes alleviate radiation-induced bone loss by restoring the function of recipient BM-MSCs and activating Wnt/β-catenin signaling
by: Rui Zuo, et al.
Published: (2019-01-01)

Salvianolic acid B inhalation solution enhances antifibrotic and anticoagulant effects in a rat model of pulmonary fibrosis
by: Tianyi Zhang, et al.
Published: (2021-06-01)

Combined assessment of the GAP index and body mass index at antifibrotic therapy initiation for prognosis of idiopathic pulmonary fibrosis
by: Yuzo Suzuki, et al.
Published: (2021-09-01)

Correction to: BM-MSC-derived exosomes alleviate radiation-induced bone loss by restoring the function of recipient BM-MSCs and activating Wnt/β-catenin signaling
by: Rui Zuo, et al.
Published: (2020-01-01)

Antifibrotic effects of total or partial application of amniotic membrane in hepatic fibrosis
by: KARINA M. MAMEDE, et al.

Amniotic MSCs reduce pulmonary fibrosis by hampering lung B‐cell recruitment, retention, and maturation
by: Anna Cargnoni, et al.
Published: (2020-09-01)

Prognostic role of MUC5B rs35705950 genotype in patients with idiopathic pulmonary fibrosis (IPF) on antifibrotic treatment
by: Davide Biondini, et al.
Published: (2021-04-01)

Antioxidant Activity Mediates Pirfenidone Antifibrotic Effects in Human Pulmonary Vascular Smooth Muscle Cells Exposed to Sera of Idiopathic Pulmonary Fibrosis Patients
by: Alessandro Giuseppe Fois, et al.
Published: (2018-01-01)